Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin vs Ciprofloxacin for SBP Prophylaxis
NCT06234046Phase 3Completed
- Sponsor
- Ain Shams University
- Start
- May 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rifaximin in spontaneous bacterial peritonitis (SBP) (2 arms), sponsored by Ain Shams University. Primary endpoint: Recurrence of Spontaneous Bacterial Peritonitis at 6 months. Started May 2023; status: completed.
02
Drugs
rifaximin
03
Conditions
spontaneous bacterial peritonitis (SBP)
Beyond the preview
Go deeper on NCT06234046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06234046.